​
​

OKYO Pharma Stock (NASDAQ:OKYO)

OwnershipFinancialsChart
OKYO Pharma by TradingView

Previous Close

$1.03

52W Range

$0.81 - $2.95

50D Avg

$1.18

200D Avg

$1.43

Market Cap

$34.85M

Avg Vol (3M)

$193.73K

Beta

-3.36

Div Yield

-

OKYO Company Profile

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

GB

Employees

8

IPO Date

May 17, 2022

Website

OKYO Performance

OKYO Financial Summary

Mar 23Mar 22Mar 21
Revenue---
Operating Income$-13.19M$-6.22M$-4.13M
Net Income$-13.27M$-5.43M$-3.35M
EBITDA$-13.18M$-6.22M$-3.35M
Basic EPS$-0.60$-0.01$-0.01
Diluted EPS$-0.60$-0.01$-0.01

Fiscal year ends in Mar 23 | Currency in USD

Peer Comparison

TickerCompany
SNTISenti Biosciences, Inc.
MGTADianthus Therapeutics, Inc.
FHTXFoghorn Therapeutics Inc.
CVKDCadrenal Therapeutics, Inc. Common Stock
PXMDPaxMedica, Inc. Common Stock
QNRXQuoin Pharmaceuticals, Ltd.
HILSTharimmune, Inc.
CMNDClearmind Medicine Inc.
VRAXVirax Biolabs Group Limited
CADLCandel Therapeutics, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
UNCYUnicycive Therapeutics, Inc.
CDIOCardio Diagnostics Holdings, Inc.